The Daily Byte
Breaking
Welcome to The Daily Byte — real stories from across Pakistan.
Saturday, 21 November 2026 · Pakistan

The Daily Byte

Stories from Pakistan that deserve to be heard
Minor Markets

Merck KGaA raises 2026 guidance third time

By The Daily Byte ·13 Nov 2026 ·2 min read
Visitors' entrance, known as the Pyramid, at Merck KGaA headquarters in Darmstadt, Germany

Germany's Merck KGaA has raised its 2026 profit guidance for the third time this year, after stronger third-quarter sales across its three businesses and a lift from favourable currency movements. The Darmstadt-based science and technology group announced the upgrade on 12 November.

Merck now expects full-year net sales of €21.5 billion to €21.9 billion, up from €21 billion to €21.8 billion, and adjusted earnings before interest, tax, depreciation and amortisation of €6.2 billion to €6.4 billion, up from €5.9 billion to €6.3 billion. Earnings per share before one-off items are forecast at €8.30 to €8.70.

Electronics leads the third quarter

Third-quarter net sales rose 5.8 per cent to €5.6 billion, with organic growth of 5.1 per cent, while adjusted EBITDA edged up 0.8 per cent to about €1.7 billion. Electronics was the strongest division, with organic growth of 13 per cent, including a 19 per cent rise in semiconductor solutions as artificial-intelligence demand lifted sales of chip materials. Life science guidance was raised to organic growth of 6–7 per cent.

Net profit fell by about half to €450 million, but the comparison was flattered by one-off gains a year earlier. The new guidance also assumes a December contribution from the planned $11.3 billion acquisition of US firm Bio-Techne.

Warning on a key drug

Management also warned that sales of its multiple sclerosis drug Mavenclad face a steep decline in 2027, a caution that tempers the otherwise confident outlook. Morningstar reported the upgrade followed earlier increases alongside first- and second-quarter results, while Reuters put the improved outlook down to better underlying performance, currency effects and the Bio-Techne deal.